Norelgestromin

Medical uses

Norelgestromin is used in combination with ethinyl estradiol in contraceptive patches. These patches mediate their contraceptive effects by suppressing gonadotropin levels as well as by causing changes in the cervical mucus and endometrium that diminish the likelihood of pregnancy.

Available forms

Norelgestromin is available only as a transdermal contraceptive patch in combination with ethinyl estradiol. The Ortho Evra patch is a 20 cm, once-weekly adhesive that contains 6.0 mg norelgestromin and 0.6 mg ethinyl estradiol and delivers 200 μg/day norelgestromin and 35 μg/day ethinyl estradiol.

Contraindications

Side effects

Norelgestromin has mostly been studied in combination with an estrogen, so the side effects of norelgestromin specifically or on its own have not been well-defined. Side effects associated with the combination of ethinylestradiol and norelgestromin as a transdermal patch in premenopausal women, with greater than or equal to 2.5% incidence over 6 to 13 menstrual cycles, include breast symptoms (including discomfort, engorgement, and/or pain; 22.4%), headaches (21.0%), application site reactions (17.1%), nausea (16.6%), abdominal pain (8.1%), dysmenorrhea (7.8%), vaginal bleeding and menstrual disorders (6.4%), mood, affect, and anxiety disorders (6.3%), vomiting (5.1%), diarrhea (4.2%), vaginal yeast infections (3.9%), dizziness (3.3%), acne (2.9%), migraine (2.7%), weight gain (2.7%), fatigue (2.6%), and pruritus (2.5%).

Overdose

Interactions

Pharmacology

Pharmacodynamics

Norelgestromin is a progestogen. It is one of the active metabolites of norgestimate. Unlike many related progestins, norelgestromin reportedly has negligible androgenic activity. However, it produces levonorgestrel as an active metabolite to some extent, which does have some androgenic activity. Nonetheless, transdermally-administered norelgestromin does not counteract the increase in sex hormone-binding globulin levels produced by ethinyl estradiol.

Pharmacokinetics

Upon application of a transdermal patch containing norelgestromin and ethinyl estradiol, plateau levels of both are reached by approximately 48 hours, and steady-state levels are reached within 2 weeks of application. Absorption following application to the buttock, upper outer arm, abdomen, and upper torso was assessed and, while absorption from the abdomen was slightly lower, it was considered to be therapeutically equivalent for the various areas. Mean levels of norelgestromin at steady-state ranged from 0.305 ng/mL to 1.53 ng/mL, with an average of about 0.725 ng/mL. The plasma protein binding of norelgestromin is 99%, and it is bound to albumin but not to sex hormone-binding globulin.

The metabolism of norelgestromin takes place in the liver and is via transformation into levonorgestrel (conversion of the C3 oxime into a ketone) as well as hydroxylation and conjugation. However, because norelgestromin is used parenterally, first-pass metabolism in the liver and gastrointestinal tract that normally occurs with oral administration are avoided. The biological half-life of norelgestromin is 17 to 37 hours. The metabolites of norelgestromin, along with those of ethinyl estradiol, are eliminated in the urine and feces.

Chemistry

Norelgestromin, also known as 17α-ethynyl-18-methyl-19-nortestosterone 3-oxime or as 17α-ethynyl-18-methylestr-4-en-17β-ol-3-one 3-oxime, is a synthetic estrane steroid and a derivative of testosterone. It is a racemic mixture of E and Z isomers, which have approximately the same activity. Norelgestromin is more specifically a derivative of norethisterone (17α-ethynyl-19-nortestosterone) and is a member of the gonane (18-methylestrane) subgroup of the 19-nortestosterone family of progestins. It is the C3 oxime derivative of levonorgestrel and the C17β deacetyl derivative of norgestimate and is also known as levonorgestrel 3-oxime and as 17β-deacetylnorgestimate. A related progestin is norethisterone acetate oxime (17α-ethynyl-19-nortestosterone 3-oxime 17β-acetate).

History

Norelgestromin was introduced for medical use in 2002.

Society and culture

Generic names

Norelgestromin is the generic name of the drug and its , , and . The combined ethinyl estradiol and norelgestromin contraceptive patch is also known by its developmental code name RWJ-10553.

Brand names

Norelgestromin is marketed under the brand names Evra, Ortho Evra, Xulane, and others, all in combination with ethinylestradiol.

Availability

Norelgestromin is marketed widely throughout the world, including in the United States, Canada, the United Kingdom, Ireland, elsewhere throughout Europe, South Africa, Latin America, Asia, and elsewhere in the world. It is not listed as being marketed in Australia, New Zealand, Japan, South Korea, China, India, or certain other countries.

Research

A transdermal gel formulation of norgelstromin and ethinyl estradiol was under development by Antares Pharma for use as a method of birth control with the code name AP-1081 but development was discontinued.

References

References

1. (August 2017). "ORTHO-CYCLEN and ORTHO TRI-CYCLEN (norgestimate/ethinyl estradiol) tablets, for oral use". U.S. Food and Drug Administration.
2. (November 2017). "PREFEST (estradiol/norgestimate) tablets". U.S. Food and Drug Administration.
3. "Norelgestromin/Ethinyl Estradiol Patch". Drugs.com.
4. (June 2009). "Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy". BMC Women's Health.
5. (2010). "Women's Health Across the Lifespan: A Pharmacotherapeutic Approach". ASHP.
6. (7 March 2016). "Exercise and Human Reproduction: Induced Fertility Disorders and Possible Therapies". Springer.
7. (17 April 2014). "First Generic Ortho Evra Patch Launched". Haymarket Media, Inc..
8. (2017). "Transdermal delivery of combined hormonal contraception: a review of the current literature". International Journal of Women's Health.
9. (2003). "Annual Reports in Medicinal Chemistry". Academic Press.
10. (14 August 2008). "Encyclopedia of Molecular Pharmacology". Springer Science & Business Media.
11. (August 2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration". Climacteric.
12. (September 1990). "Pharmacokinetics of oestrogens and progestogens". Maturitas.
13. (October 1999). "The pharmacological profile of a novel norpregnance progestin (trimegestone)". Gynecological Endocrinology.
14. (May 2025). "ORTHO EVRA (norelgestromin / ethinyl estradiol TRANSDERMAL SYSTEM)". U.S. Food and Drug Administration.
15. "Process for obtaining norelgestromin in different relations of isomers E and Z".
16. (8 September 2015). "Pharmacology for Women's Health". Jones & Bartlett Publishers.
17. (7 November 2007). "The Handbook of Contraception: A Guide for Practical Management". Springer Science & Business Media.
18. (2007). "Combined Estrogen-progestogen Contraceptives and Combined Estrogen-progestogen Menopausal Therapy". World Health Organization.
19. (14 November 2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer.
20. (2012). "Annual Reports in Medicinal Chemistry". Academic Press.
21. "Norelgestromin - brand name list from". Drugs.com.
22. "Ethinylestradiol/Norelgestromin transdermal - Johnson & Johnson". Springer Nature Switzerland AG.
23. "Ethinylestradiol/Norelgestromin". Springer Nature Switzerland AG.